Competition watchdog fines pharma firm over pricing of crucial thyroid drug

Competition watchdog fines pharma firm over pricing of crucial thyroid drug he UK’s competition watchdog has handed a pharmaceutical company a multimillion-pound fine after it increased the price of some thyroid medication by more than 6,000%. An investigation by the [Competition](/topic/competition) and Markets Authority (CMA) found from 2009 until 2017 Advanz charged “excessive and unfair prices” for supplying liothyronine tablets, which are used to treat thyroid hormone deficiency.

Read the source article at London news
2021-07-29 09:26:10